Neue, effektive Therapieoptionen für Patienten mit Psoriasis stehen kurz vor der Zulassung. Dabei setzen Therapien gegen die Interleukine (IL)-17 und -23 neue Maßstäbe in der Wirksamkeit. Ihre Effektivität und Sicherheit wurde in zahlreichen Studien untersucht.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Frleta M, Siebert S, McInnes IB. The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis:Disease Pathogenesis and Possibilities of Treatment. Curr Rheumatol Rep 2014;16:414
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496–509
Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized,double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168:402–11
Reich K , Puig L, Draelos Z, Notter M, Papavassilis C. Sustainability of Response With Secukinumab to 52 Weeks in Moderate-to-Severe Plaque Psoriasis: Data From the Full Year Investigative Examination of Secukinumab vs. Etanercept Using 2 Dosing Regimens to Determine Efficacy in Psoriasis (FIXTURE) Study. Poster 8101 AAD 2014 Denver
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S,Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 2014;371:326–38
Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C for the CAIN457A2211 study group. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014 Jan 7. doi: 10.1111/jdv.12359. [Epub ahead of print]
Philipp S, Fretzin S, Notter M, Papavassilis C for the FIXTURE Study group. Secukinumab Effect on Functional Ability in Subjects With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: A Subanalysis From the FIXTURE Study. Poster 8098, AAD 2014
Mrowietz U, Toth D, Leonardi C, Thurston H, Papavassilis C for the SCULPTURE Study Group Secukinumab Retreatment-as-Needed Maintenance Regimen: Efficacy and Safety Outcomes From the SCULPTURE Study (Study comparing secukinumab use in long-term psoriasis maintenance therapy: fixed regimens vs. retreatment upon start of relapse [SCULPTURE]) Poster 8229 AAD Denver 2014
Elewski B, Lebwohl M, Papp K, Nakagawa H, Sigurgeirsson B, Tsai T, Tyring S, Hampele I, Karpov A, Helou S, Papavassilis C, for the ERASURE study group. Secukinumab in subjecst with moderate to severe plaque psoriasis: results from the efficacy of response and safety of 2 fixed doses secUkinumab Regimens in psoriasis (ERASURE), a pivotal phase 3 study. Poster 1501 EADV Istanbul 2013
Leonardi L, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-Interleukin-17 monoclonal antibody Ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190–9
Gordon KB, Leonardi L, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson E, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014 http://dx.doi.org/10.1016/j.jaad.2014.07.048.
Gordon KB, Leonardi C, Lebwohl M, Braun D, Cameron GS, Banerjee S, Kenneth B. Safety Profile of Ixekizumab, an Anti-IL-17 Monoclonal Antibody, in Chronic Plaque Psoriasis Patients After at Least 1 Year of Open-label Treatment Poster 7617 AAD 2014 Denver
Papp KA, Leonardi C, Menter A, Ortonne JP,Krueger JG, Kricorian G, Aras G, Li J, Russell, CB, Thompson EHZ, Baumgartner SN. Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis. Engl J Med 2012;366:1181–9.
Papp K, Leonardi C, Menter A, Ortonne JP, Milmont CE, Nirula A, Klekotka P Maintenance of clinical response with longterm brodalumab therapy for psoriasis:week 96 results from an open-label extension study. Poster 0687 EADV Istanbul Oct 2013
Papp K, Leonardi C, Menter A,Thompson EHZ, Milmont CE, Nirula A, Klekotka P. Maintenance of Clinical Response With Long-term Brodalumab (AMG 827) Therapy for Psoriasis: Week 96 Results From an Open-label Extension Study. Poster 8418 AAD Denver March 2014
Thaci D, Papp K, Langley RG, Reich K, Li Q, Zhou Y, Shames R. Tildrakizumab (MK-3222), an anti-IL23p19 monoclonal antibody improves psoriasis in a phase2b randomized, placebo-controlled trial. Poster EADV Istanbul Oct 2013
Reich K , Langley RG, Papp K, Thaci D, Li Q, Zhou Y, Shames R .Treatment with an anti- IL-23p19 humanized monoclonal antibody (tildrakizumab, MK-3222) provides significant improvement in psoriasis that is maintained up to 52 week. Poster EADV Istanbul Oct 2013
Callis-Duffin K, Gordon K, Wasfi Y, Shen YK. A phase 2 multicenter, randomized, placebo- and active-comparator controlled, dose-ranging trial to evaluate guselkumab for the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE). P8353 AAD 2014 Denver
Kofoed K, Skov L, Zachariae C. New Drugs and Treatment Targets in Psoriasis. Acta Derm Venereol 2014 Aug 11. doi: 10.2340/00015555-1931. [Epub ahead of print]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Philipp, S. Teil 1: neue gegen IL-17 und IL-23 gerichtete Therapien. hautnah dermatologie 31, 30–36 (2015). https://doi.org/10.1007/s15012-015-1754-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15012-015-1754-7